VALUATION AND QUALIFYING ACCOUNTS (Notes)

12 Months Ended

Dec. 31, 2021

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

VALUATION AND QUALIFYING ACCOUNTINGS

(In millions) For the years ended Dec 31,	2021		2020		2019
Accounts Receivable - Allowance for Doubtful Receivables
Balance at beginning of year	$	51	$	45	$	42
Additions charged to expenses 1	16		22		24
Deductions from reserves 2	(13)		(16)		(21)
Balance at end of year	$	54	$	51	$	45
Inventory - Obsolescence Reserve
Balance at beginning of year	$	23	$	35	$	23
Additions charged to expenses	3		2		19
Deductions from reserves 3	(12)		(14)		(7)
Balance at end of year	$	14	$	23	$	35
Reserves for Other Investments and Noncurrent Receivables
Balance at beginning of year	$	2,093	$	2,215	$	460
Additions charged to expenses 1	19		7		1,758
Deductions from reserves 4	(79)		(129)		(3)
Balance at end of year	$	2,033	$	2,093	$	2,215
Deferred Tax Assets - Valuation Allowance
Balance at beginning of year	$	1,302	$	1,262	$	1,225
Additions charged to expenses	201		313		140
Deductions from reserves	(112)		(273)		(103)
Balance at end of year	$	1,391	$	1,302	$	1,262

1.In 2019, additions charged to expenses for "Accounts Receivable - Allowance for Doubtful Receivables" included $2 million and additions charged to expenses for "Reserves for Other Investments and Noncurrent Receivables" included $1,753 million related to the Company's investment in Sadara Chemical Company ("Sadara"). See Note 12 to the Consolidated Financial Statements for additional information.

2.Deductions included write-offs, recoveries, currency translation adjustments and other miscellaneous items.

3.Deductions included disposals and currency translation adjustments.

4.Deductions from reserves for "Reserves for Other Investments and Noncurrent Receivables" included $77 million in 2021 and 2020 related to the Company's investment in Sadara. See Note 12 to the Consolidated Financial Statements for additional information.